Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) is one of 952 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Cadrenal Therapeutics to similar businesses based on the strength of its dividends, risk, valuation, institutional ownership, profitability, analyst recommendations and earnings.
Analyst Ratings
This is a breakdown of current ratings for Cadrenal Therapeutics and its peers, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Cadrenal Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Cadrenal Therapeutics Competitors | 6244 | 18207 | 42955 | 875 | 2.56 |
Cadrenal Therapeutics currently has a consensus price target of $3.50, suggesting a potential upside of 729.97%. As a group, “Pharmaceutical preparations” companies have a potential upside of 80.71%. Given Cadrenal Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Cadrenal Therapeutics is more favorable than its peers.
Institutional & Insider Ownership
Valuation and Earnings
This table compares Cadrenal Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Cadrenal Therapeutics | N/A | -$8.36 million | -0.61 |
Cadrenal Therapeutics Competitors | $1.96 billion | $98.43 million | -4.64 |
Cadrenal Therapeutics’ peers have higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Cadrenal Therapeutics has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics’ peers have a beta of 0.79, suggesting that their average stock price is 21% less volatile than the S&P 500.
Profitability
This table compares Cadrenal Therapeutics and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Cadrenal Therapeutics | N/A | -128.67% | -117.76% |
Cadrenal Therapeutics Competitors | -2,646.05% | -227.44% | -30.04% |
Summary
Cadrenal Therapeutics beats its peers on 8 of the 13 factors compared.
Cadrenal Therapeutics Company Profile
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.